Title:
インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
Document Type and Number:
Japanese Patent JP7145374
Kind Code:
B2
Abstract:
The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.
More Like This:
Inventors:
Phosphorus, cyan-yo
Bertino, Joseph, Earl.
Lin, Chen-Yeon
Sakei, Zoltan
Bertino, Joseph, Earl.
Lin, Chen-Yeon
Sakei, Zoltan
Application Number:
JP2018549206A
Publication Date:
October 03, 2022
Filing Date:
March 17, 2017
Export Citation:
Assignee:
Rutgers The State University of New Jersey
International Classes:
A61K47/68; A61K31/40; A61K39/395; A61K47/60; A61K47/65; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| JP2013543003A | ||||
| JP2015209426A | ||||
| JP2009521913A |
Foreign References:
| WO2015075477A1 | ||||
| US20160015728 | ||||
| WO2015188934A1 |
Attorney, Agent or Firm:
Patent business corporation Kita Aoyama International